Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for autoimmune disorders and chronic inflammatory diseases. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements and corporate developments.
Access authoritative information on NKTR's pipeline progress, including updates on rezpegaldesleukin (Treg stimulator) and NKTR-255 (IL-15 agonist). Our curated collection features press releases about clinical trial milestones, regulatory submissions, strategic partnerships, and financial disclosures.
Key content categories include therapy development breakthroughs, FDA communications, research collaborations, and manufacturing updates. All materials are sourced directly from official company channels to ensure accuracy and compliance.
Bookmark this page for streamlined access to NKTR's latest developments in polymer conjugate chemistry and immunomodulation research. Check regularly for updates that could inform your understanding of the company's scientific trajectory and market position.
Nektar Therapeutics (Nasdaq: NKTR) management will present at two upcoming investor conferences: the Jefferies Healthcare Conference in New York City on June 6, 2024, at 3:30 p.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024, at 2:00 p.m. ET.
The presentations will be webcast live and accessible via the Investor Events section on the Nektar website. Recordings of the webcasts will be available until July 6, 2024, and July 10, 2024, respectively.
Nektar Therapeutics reported their financial results for the first quarter of 2024, showing revenue of $21.6 million and a net loss of $36.8 million. The company's cash and investments were $326.0 million as of March 31, 2024, supporting operations until the third quarter of 2026. Progress was noted in their immunology and inflammation pipeline, with expectations for topline data from ongoing trials in 2025. Nektar also entered into a private placement financing agreement generating $30 million in gross proceeds.
Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and CEO, will host a conference call to review the results. The press release and webcast link will be available on the Nektar website. Conference call replay will be accessible until June 9, 2024.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
